Zoldonrasib (Synonyms: RMC-9805; KRAS G12D inhibitor 18)

Name: Zoldonrasib
Brand: MedChemExpress
SKU: HY-156819
Rating: 5.0 (5 reviews)

Cat. No.: HY-156819 Purity: 99.52%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer.

For research use only. We do not sell to patients.

CAS No. : 2922732-54-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

5 Publications Citing Use of MCE Zoldonrasib

In Vivo Efficacy Study

Bio/Physico-chemical Assay

Cell Proliferation/Viability Assay

: Zoldonrasib purchased from MedChemExpress. Usage Cited in: Nature. 2026 Feb;650(8102):748-758. [Abstract]; Liver metastatic burden in AKPT treated from 7 days post-transplantation and continued for 21 days. RMC9805 (100 mg/kg, oral, daily, 3 weeks) versus RMC6236 versus combined RMC9805–RMC6236 versus vehicle are shown.

: Zoldonrasib purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 Jan 8;86(1):60-77.e7. [Abstract]; Western blotting of AURKA, SRSF1, MYC, phosphorylated and total ERK1/2 (p-ERK and t-ERK, respectively), and VINC from SUIT2 parental cells and SUIT2 RMC-9805-resistant cells. Cells were either treated with DMSO, RMC-9805 (1 μM), or RMC-9805 (1 μM) + SC or ASO-A (65 nM) for 48 h.

: Zoldonrasib purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 Jan 8;86(1):60-77.e7. [Abstract]; Parental cells were sensitive to RMC-9805 (1 μM, 48 h), showing reduced extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation (p-ERK), drug-resistant cells, on the other hand, maintain mitogen-activated protein kinase (MAPK) signaling.

: Zoldonrasib purchased from MedChemExpress. Usage Cited in: Mol Cell. 2026 Jan 8;86(1):60-77.e7. [Abstract]; Parental cells were sensitive to RMC-9805 (1 μM, 48 h), resulting in decreased cell viability, while drug-resistant cells maintained cell viability.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

View All Isoforms

K-Ras H-Ras N-Ras Ras

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

KRAS(G12D)

In Vitro

Zoldonrasib (RMC-9805) (100 nM; 48 h) inhibits the production of CXCL1, GM-CSF and decreases the production of CXCL10, CCL17 in eCT26 (KRASG12D/G12D) cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Zoldonrasib (RMC-9805) (100 mg/kg; po; once daily for 4-8 days) shows antitumor activity in KRAS G12D xenograft models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice^[2]
Dosage:	100 mg/kg
Administration:	PO; once daily for 4-8 days
Result:	Decreased the level of myeloid cells, such as mMDSC, gMDSC, M2 TAMS, increased the level of cytotoxic T cells including CD3e⁺, CD4⁺, CD8⁺ T cells.

Clinical Trial

Molecular Weight

1168.44

Formula

C₆₃H₈₈F₃N₁₁O₇

CAS No.

2922732-54-3

Appearance

Solid

Color

White to yellow

SMILES

O=C([C@H]1NN(C([C@@H](NC([C@@H](N2C[C@]3(CN(C([C@@H]4N(C)[C@@H]4C5CC5)=O)CC3)CC2)C6CCCC6)=O)C[C@H]7CN8CCO7)=O)CCC1)OCC(C)(C)CC9=[C@@]([C@@]%10=C([C@@H](OC)C)N=CC(N%11CCN(C%12CC%12)CC%11)=C%10)N(CC(F)(F)F)C%13=C9C=C8C=C%13

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (85.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8558 mL	4.2792 mL	8.5584 mL
5 mM	0.1712 mL	0.8558 mL	1.7117 mL
10 mM	0.0856 mL	0.4279 mL	0.8558 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.14 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.73%

Select Batch:

Data Sheet (278 KB) SDS (252 KB)

COA (255 KB) HNMR (359 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. BLAKE JAMES F, et al. Preparation of peptide-linked macrocyclic dipeptides as Ras inhibitors.World Intellectual Property Organization, WO2023060253 A1 2023-04-13

[2]. Knox, J et al.RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models. Cancer Res 1 April 2023; 83 (7_Supplement): 3475

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.8558 mL	4.2792 mL	8.5584 mL	21.3961 mL
	5 mM	0.1712 mL	0.8558 mL	1.7117 mL	4.2792 mL
	10 mM	0.0856 mL	0.4279 mL	0.8558 mL	2.1396 mL
	15 mM	0.0571 mL	0.2853 mL	0.5706 mL	1.4264 mL
	20 mM	0.0428 mL	0.2140 mL	0.4279 mL	1.0698 mL
	25 mM	0.0342 mL	0.1712 mL	0.3423 mL	0.8558 mL
	30 mM	0.0285 mL	0.1426 mL	0.2853 mL	0.7132 mL
	40 mM	0.0214 mL	0.1070 mL	0.2140 mL	0.5349 mL
	50 mM	0.0171 mL	0.0856 mL	0.1712 mL	0.4279 mL
	60 mM	0.0143 mL	0.0713 mL	0.1426 mL	0.3566 mL
	80 mM	0.0107 mL	0.0535 mL	0.1070 mL	0.2675 mL

Zoldonrasib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zoldonrasib2922732-54-3RMC-9805 KRAS G12D inhibitor 18RMC9805RMC 9805RasApoptosisapoptosisKRAS G12D mutantanticancerorally activeInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Zoldonrasib (Synonyms: RMC-9805; KRAS G12D inhibitor 18)

Customer Review

Zoldonrasib Related Antibodies

5 Publications Citing Use of MCE Zoldonrasib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Zoldonrasib Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Zoldonrasib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report